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Overall response rate (ORR) for all sites was 89.2% (33/37 
sites). 17 sites (45.9%) achieved a complete response (CR) 
and 16 sites (43.2%) a partial response. 4 sites (10.8%) did not 
respond to LDRT. Considering ORR by patient, 11/15 patients 
(73.3%) had a response to LDRT at all sites, 3/15 (20%) did 
not respond and 1 patient responded at 2 sites but not the 
3rd. 
Skin was the most commonly treated site (19/37, 51.4%) and 
skin sites had the highest ORR at 100%, with 73.7% (14/19) 
CR. This was statistically significant when compared to all 
other sites (p=0.046). ORR for nodal sites was 83.3% (5/6) and 
extra-nodal sites was 85.7% (6/7). Bone sites had the lowest 
ORR at 60% (3/5 cases) with no CR.  
16 sites received a total dose of 4Gy in 1 or 2 fractions. 21 
sites received either 6 or 8Gy in total. ORR in both groups 
was similar (87.5% versus 90.5%, p =1). Toxicity from LDRT 
was minimal, with no toxicity recorded above grade 2.  
Of the 33 initially responding sites there have been 4 infield 
recurrences (12.1%). Median TTP was 4.8 months (3.1-11.8). 
2 sites were retreated with further symptomatic benefit. 
Median duration of response was 3.6 months (0.5-126.7). 6 
sites (2 patients) had responses lasting >30 months. The 
majority of patients died without documented local 
recurrence, with median overall survival from LDRT of 2.4 
months (0.03-126.7). 
 
Conclusion: LDRT is an effective palliative treatment for 
patients with RR HGNHL and anticipated short survival, 
achieving high response rates and excellent local control, 
with minimal toxicity and inconvenience. A small subgroup of 
patients with slowly relapsing disease derived durable 
remissions with LDRT. 
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Purpose or Objective: Hodgkin lymphoma (HL) has become a 
highly curable lymphoid malignancy. The improved prognosis 
of HL has been accompanied by increasing incidence of 
adverse late effects. Mediastinal radiotherapy (RT) and 
cardiotoxic chemotherapy (CT) with anthracyclines are 
routinely used to treat HL, but they could be associated with 
a variety of cardiovascular complications in long-term HL 
survivors. The aim of this study is to evaluate the late 
cardiovascular toxicity of a series of 202 patients treated 
from 1995 to 2012. 
 
Material and Methods: 420 patients (pts) were treated for HL 
with RT +/- CT at our institution from 1995 to 2012. All the 
alive patients were contacted and invited to participate to 
the study. A detailed medical history of the 202 pts who 
accepted and subscribed informed consent was obtained, 
collecting events occurred after treatment; they had medical 
examination, ECG, Echocardiogram TT and blood tests. 
Treatment features were extracted from medical records. 
The entire group was divided in two groups: 157 pts received 
mediastinal RT (cases) and 45 pts did not (controls). The 
cardiac events were categorized using CTCAE ver. 4.0. A 
preliminary descriptive statistic using SPSS® software (χ2 
test) has been performed and here presented. The contouring 
of the different cardiac structures for dosimetric evaluation 
is ongoing. 
 
Results: The patients and therapeutic characteristics of the 
patients are summarized in Table 1. After a median follow-up 
of 8 years (range 2-20 years) 144 pts (71,3%) manifested 
cardiac alterations: 1,0% arrhythmia, 2,5% ischemia, 1,5% 
heart failure and 66,3% valvular fibrosis without statistical 
differences between cases and controls. Most patients 
(75,4%) had asymptomatic grade I-II valvular fibrosis; only 
one had grade III valvular fibrosis. After treatment, with a 
median follow up time of 11,2 years, (range 4,1-17,8 years), 





Conclusion: The study does not show a direct association 
between late cardiac toxicity and mediastinal RT. Multi-
parametric statistical analysis to evaluate a possible 
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correlation between the different variables and cardiac 
damage is ongoing. 
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Purpose or Objective: To evaluate the rate of complications 
and the aesthetic outcome in previously irradiated patients 
who underwent mastectomy and subsequent prosthetic 
reconstruction in 2 times. 
 
Material and Methods: Eighty-three patients who underwent 
immediate postmastectomy reconstruction with tissue 
expander between January of 2003 and June of 2012 at the 
Campus Bio-Medico University Hospital in Rome were 
retrospectively divided into two groups: Group A (study 
group) included 30 patients with previous quadrantectomy 
and radiotherapy who underwent salvage mastectomy after 
local recurrence and Group B (control group) included 53 
patients submitted to primary radical mastectomy. Patients 
and disease characteristics were analysed and complications 
were correlated to treatment group. 
 
Results: The median follow-up time for the whole group was 
36 months (range= 12-144 months). Between group A and 
group B, there were no significant differences in terms of 
age, body mass index, comorbidities, pathological stage, 
treatments data (p=NS). In Group A 25/30 patients (83.33%) 
completed heterologous reconstruction. In 5 patients 
(16.67%) a conversion to combined or solely autologous 
reconstruction was needed. In Group B, 52/53 patients 
(98.11%) completed heterologous reconstruction. In 1 case 
(1.88%) the expander was removed due to infection and an 
autologous reconstruction was performed. Revision surgery 
was needed in 5 patients (9.4%). Autologous salvage 
reconstruction was more frequent for Group A patients 
(relative risk 10.4, p=0.02). The overall rate of complications 
was not different between the two groups (66.6% vs 58.5%; 
p=0.49) even if major complications (vast necrosis of 
mastectomy flaps with or without partial implant exposure, 
with or without implant removal, all III and IV-degree 
capsular contractures, either requiring or not requiring 
further surgery) were non significantly higher in the 
irradiated group (53.3% vs 32.0%; p= 0.07). However, 
analysing capsular contracture, a significantly higher risk of 
grade III-IV were recorded in Group A (40% vs 15%; relative 
risk 3.75, p=0.02). In Group A the median time from RT to 
reconstruction was 24 months (range= 9-192 months) and the 
incidence of major complications was not related to time 
from RT to reconstruction (p=0.313).  
 
Conclusion: Heterologus reconstruction after salvage 
mastectomy in previously irradiated patients, is still possible 
with satisfactory results. 
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Purpose or Objective: Germline polymorphisms in oxidative 
stress response genes have been postulated to be involved in 
the development of late normal tissue complications 
following radiotherapy. Despite the key role of mitochondria 
in the production of reactive oxygen species, the contribution 
of mitochondrial DNA variations to clinical radiosensitivity is 
still largely unknown. In the present study, we evaluated the 
association between mitochondrial DNA haplogroups and the 
risk of radiation-induced subcutaneous fibrosis after 
postoperative radiotherapy in breast cancer patients. 
 
Material and Methods: Subcutaneous fibrosis was scored 
according to the Late Effects of Normal Tissue-Subjective 
Objective Management Analytical (LENT-SOMA) scale in 286 
Italian breast cancer patients who received radiotherapy 
after breast conserving surgery. Eight mitochondrial DNA 
(mtDNA) SNPs that define the nine major haplogroups in the 
European population were determined by PCR–RFLP analysis 
on genomic DNA extracted from peripheral blood. 
 
Results: In a Kaplan-Meier analysis evaluated by the log-rank 
test, carriers of haplogroup H were found at lower risk of 
grade ³2 subcutaneous fibrosis (P=0.018). In the multivariate 
Cox regression analysis adjusted for clinical factors (BMI, 
breast diameter, adjuvant treatment, dose per fraction, 
radiation type and acute skin toxicity), the haplogroup H 
emerged as significant protective factor for moderate to 
severe radiation-induced fibrosis (HR: 0.50, 95% CI 0.27-0.92, 
P=0.027). 
 
Conclusion: Our results support a protective role of the 
mitochondrial haplogroup H in the development of radiation-
induced fibrosis in breast cancer patients. Further 
prospective studies with larger sample size and different 
populations are nevertheless warranted to corroborate the 
possible influence of mitochondrial haplogroups on late 
normal tissue radiosensitivity. 
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Purpose or Objective: The Young Boost trial (YBT), a 
multicenter RCT (NCT00212121), investigates whether a 
higher boost dose leads to a lower recurrence rate in young 
patients treated with breast conserving therapy. Cosmetic 
outcome is the secondary objective. The aim of the current 
analysis is to investigate the factors influencing the patients’ 
opinion about cosmesis.  
 
Material and Methods: From 2004-2011, 2421 breast cancer 
patients ≤ 50 yrs were included in The Netherlands, France, 
and Germany. All patients were treated with lumpectomy, 
followed by 50 Gy whole breast irradiation. Patients were 
randomized to receive a standard 16 Gy (n=1211) or a high 26 
Gy boost (n=1210) to the tumour bed. Cosmetic outcome data 
at 4 years of 807 patients were used for the current analysis 
according to the following two scoring systems:  
1. BCCT.core: Digital photographs were analyzed using a 
software program to extract an overall cosmetic score: 
excellent, good, fair or poor. This score is based on 
symmetry, skin color and scar visibility. The 7 features of 
symmetry in the BCCT.core program are: nipple position 
(pBRA), level of lower breast contour (pLBC), level of nipple 
(pUNR), distance from nipple to inframammary fold (pBCE), 
length of breast contour (pBCD), area of the breast (pBAD) 
and non-overlapping area between left and right breast 
(pBOD). 2. Patients’ score using a validated patient’s 
questionnaire about the breast appearance, including an 
overall score: very satisfied, satisfied, not dissatisfied, 
dissatisfied or very dissatisfied. First, we analyzed the 7 
features of BCCT.core in a proportional odds model, to 
